Overview

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nemours Children's Clinic
Collaborators:
AstraZeneca
EMD Serono
Genentech, Inc.
Treatments:
Anastrozole
Hormones